Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10591140 | Bioorganic & Medicinal Chemistry Letters | 2014 | 20 Pages |
Abstract
CEP-32496 is a novel, orally active serine/threonine-protein kinase B-raf (BRAF) (V600E) kinase inhibitor that is being investigated in clinical trials for the treatment of some cancers in patients. In this study, we developed [11C-carbonyl]CEP-32496 as a novel positron emission tomography (PET) probe to study its biodistribution in the whole bodies of mice. [11C]CEP-32496 was synthesized by the reaction of 5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-amine hydrochloride (1·HCl) with [11C]phosgene, followed by treatment with 3-(6,7-dimethoxyquinozolin-4-yloxy)aniline (2). Small-animal PET studies with [11C]CEP-32496 indicated that radioactivity levels (AUC0-90 min, SUV Ã min) accumulated in the brains of P-gp/BCRP knockout mice at a 8-fold higher rate than in the brains of wild-type mice.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Yoko Shimoda, Joji Yui, Masayuki Fujinaga, Lin Xie, Katsushi Kumata, Masanao Ogawa, Tomoteru Yamasaki, Akiko Hatori, Kazunori Kawamura, Ming-Rong Zhang,